Valneva Engages Investors at Major U.S. and European Conferences

Valneva to Engage Institutional Investors at Leading Conferences

Valneva SE (NASDAQ: VALN; Euronext Paris: VLA), a renowned specialty vaccine firm, is set to actively engage with institutional investors at major upcoming healthcare conferences across the globe. This is an exciting opportunity for the company to showcase its advancements and discuss its strategic direction.

Leadership Discussions on Vaccine Pipeline

Attending the conferences will be Valneva's Chief Executive Officer, Thomas Lingelbach, along with Chief Financial Officer, Peter Bühler. They will conduct moderated "fireside chat" sessions designed to provide insight into the company’s key value drivers and upcoming catalysts, mainly focusing on the essential clinical data expected in 2025. One of the highlights will be detailed discussions around the Phase 3 results for VLA15, Valneva's flagship vaccine candidate targeting Lyme disease. This candidate is currently being developed in collaboration with Pfizer, with the prospect of key regulatory submissions in both the U.S. and European markets slated for 2026, contingent on successful trial outcomes.

Upcoming Conference Schedule

Guggenheim Inaugural Healthcare Innovation Conference

This event is scheduled for November 12 at 3:30 PM EST and will primarily consist of a fireside chat, alongside focused investor meetings in Boston, Massachusetts.

Jefferies London Healthcare Conference

On November 19 at 8:00 AM GMT, Valneva will take part in another fireside chat at the Jefferies London Healthcare Conference. In addition to the live discussions, a replay of the session will be made available in the Investor section of Valneva's corporate website.

Connecting with Investors

Valneva encourages institutional investors interested in meeting with the company's management during these conferences to reach out through their bank representatives. This emphasizes the company’s commitment to transparency and open communication with its stakeholders.

About Valneva SE

Valneva SE is dedicated to the development and commercialization of innovative vaccines designed to tackle infectious diseases that often go unaddressed. With a focus on delivering breakthrough solutions, the company utilizes its vast expertise across various vaccine technologies to create first-, best- or only-in-class offerings. Valneva has an impressive track record, successfully advancing multiple vaccines from early research stages to market availability.

The firm currently markets three proprietary vaccines for travelers, including the world's first and only chikungunya vaccine. Revenues from these initiatives support the continuous development of their promising vaccine pipeline, which includes the only advanced Lyme disease vaccine candidate in clinical trials, along with candidates for Shigella, Zika virus, and other globally significant health threats. More details are accessible via the Valneva website.

Contact Information

Valneva Investor and Media Contacts

Laetitia Bachelot-Fontaine
VP, Global Communications and European Investor Relations
M +33 (0)6 4516 7099
investors@valneva.com

Joshua Drumm, Ph.D.
VP, Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com

Frequently Asked Questions

What is the purpose of Valneva attending these conferences?

Valneva's participation in these conferences is to engage with institutional investors, presenting their future plans and discussing ongoing and upcoming clinical data.

Who from Valneva will be presenting at the conferences?

Valneva's CEO, Thomas Lingelbach, and CFO, Peter Bühler, will be leading the discussions at these events.

What vaccine candidate will be highlighted during these discussions?

The discussions will focus on VLA15, Valneva’s Lyme disease vaccine candidate, which is currently in advanced development in collaboration with Pfizer.

When are these conferences taking place?

The Guggenheim Conference is on November 12, and the Jefferies Conference is on November 19.

How can investors arrange meetings with Valneva leadership?

Interested institutional investors can request meetings with Valneva’s management through their bank representatives.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.